Literature DB >> 7714611

The role of the epidermal growth factor receptor in human gliomas: I. The control of cell growth.

U Hoi Sang1, O D Espiritu, P Y Kelley, M R Klauber, J D Hatton.   

Abstract

The epidermal growth factor receptor (EGFR) gene is amplified in over 40% of primary human glioblastomas and overexpressed in the majority. The authors' investigations demonstrate that the function of the EGFR in glioblastomas is distinct from that in other human cancers because it does not appear to mediate the primary growth-promoting effect of EGF. Findings show that the level of EGFR expression does not directly predict the growth response to EGF, with growth stimulated in some cells but inhibited in others when cells were cultured in plastic dishes. On the other hand, when human glioblastoma cells were placed in soft agar cultures, the cell line expressing the highest levels of the EGFR demonstrated considerable colony formation in response to EGF treatment. In addition, cell lines with the highest EGFR levels were also more resistant to the growth-suppressive effects of retinoic acid when maintained in soft agar. These observations suggest that even though the overexpression of the EGFR did not confer a distinct growth advantage to glioma cells cultured on flat culture dishes, the ability of these cells to maintain anchorage-independent growth in soft agar especially in response to EGF and retinoic acid is facilitated. Because anchorage-independent growth is the best in vitro correlate to tumorigenicity, amplification and overexpression of the EGFR in human glioblastoma cells may be in part responsible for the tumorigenic potential of these cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714611     DOI: 10.3171/jns.1995.82.5.0841

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

1.  Effects of growth factors and basement membrane proteins on the phenotype of U-373 MG glioblastoma cells as determined by the expression of intermediate filament proteins.

Authors:  S Sultana; R Zhou; M S Sadagopan; O Skalli
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

Review 2.  Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs.

Authors:  I F Dunn; O Heese; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

3.  Alteration in p53 modulates glial proteins in human glial tumour cells.

Authors:  H S U; A Banaie; L Rigby; J Chen; H Meltzer
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

4.  Bcl-2 expression in higher-grade human glioma: a clinical and experimental study.

Authors:  C Fels; C Schäfer; B Hüppe; H Bahn; V Heidecke; C M Kramm; C Lautenschläger; N G Rainov
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

5.  Glutamate promotes cell growth by EGFR signaling on U-87MG human glioblastoma cell line.

Authors:  Daniel Pretto Schunemann; Ivana Grivicich; Andréa Regner; Lisiane Freitas Leal; Daniela Romani de Araújo; Geraldo Pereira Jotz; Carlos Alexandre Fedrigo; Daniel Simon; Adriana Brondani da Rocha
Journal:  Pathol Oncol Res       Date:  2009-12-08       Impact factor: 3.201

6.  Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells.

Authors:  Sami Khoshyomn; David Nathan; Gregory C Manske; Turner M Osler; Paul L Penar
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

7.  Molecular genetic changes in a series of neuroepithelial tumors of childhood.

Authors:  Alessia Di Sapio; Isabella Morra; Luca Pradotto; Marilena Guido; Davide Schiffer; Alessandro Mauro
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

8.  Genome-scale identification of membrane-associated human mRNAs.

Authors:  Maximilian Diehn; Ramona Bhattacharya; David Botstein; Patrick O Brown
Journal:  PLoS Genet       Date:  2006-01-13       Impact factor: 5.917

9.  Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.

Authors:  Stephanie E Combs; Steffen Heeger; Renate Haselmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  BMC Cancer       Date:  2006-05-18       Impact factor: 4.430

10.  Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.

Authors:  Zarina Yelskaya; Vangie Carrillo; Ewa Dubisz; Hira Gulzar; Devon Morgan; Shahana S Mahajan
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.